TRMT112 and brain glioma: Higher TRMT112 expression predicted poorer OS among patients with adrenocortical carcinoma (ACC, P=0.046), HNSC (P=0.0014), lower-grade brain glioma (LGG, P=0.0012), LIHC (P=0.0028), and pancreatic adenocarcinoma (PAAD, P=0.018) (Figure 2).